In a landmark development for hematologic oncology, the Phase II ImmunoPRISM trial has unveiled transformative data that could shift the paradigm of how clinicians approach high-risk smoldering multiple myeloma (SMM). Presented at the European Hematology Association (EHA) Congress in Stockholm, the study demonstrates that teclistamab—a B-cell maturation antigen (BCMA)-targeted bispecific antibody—significantly outperforms the current standard of care.
For decades, the medical community has grappled with the "watch and wait" approach for SMM, a precursor condition characterized by a high risk of progression to symptomatic, life-threatening multiple myeloma. The findings from the Dana-Farber Cancer Institute suggest that the era of passive observation may be drawing to a close, replaced by an aggressive, immunologically driven strategy of "interception."
Main Facts: The ImmunoPRISM Breakthrough
The ImmunoPRISM trial stands as the first randomized clinical study to evaluate the efficacy of a BCMA-targeted bispecific antibody in the setting of high-risk smoldering multiple myeloma.
Multiple myeloma is a cancer of the plasma cells, and smoldering myeloma is its asymptomatic, pre-malignant phase. Approximately 50% of patients diagnosed with high-risk SMM will progress to active, symptomatic multiple myeloma within just two years. Historically, the standard of care has been simple observation; while some clinical trials have utilized combinations like lenalidomide and dexamethasone to delay progression, these treatments often fail to achieve deep, durable remissions.
Teclistamab functions by acting as a bridge, binding simultaneously to BCMA on the surface of myeloma cells and the CD3 receptor on T cells. This mechanism effectively recruits the patient’s own immune system to identify, target, and destroy malignant cells. The ImmunoPRISM trial enrolled 59 patients to determine whether moving this powerful immunotherapy to an earlier stage of disease could provide superior outcomes compared to standard pharmacotherapy.
Chronology of the Clinical Investigation
The path to the recent EHA Congress presentation represents years of iterative research into immune-based cancer interception.
- Pre-Trial Rationale: Researchers at the Dana-Farber Cancer Institute, led by Dr. Omar Nadeem and Dr. Irene Ghobrial, hypothesized that the immune system of patients with smoldering myeloma is more "fit" than that of patients with relapsed or refractory disease. They proposed that introducing T-cell redirection therapy before the immune system is exhausted by multiple lines of treatment—and before the cancer evolves into a more aggressive phenotype—could fundamentally alter the disease trajectory.
- Study Enrollment: The ImmunoPRISM trial was structured to evaluate high-risk SMM patients. Of the 59 participants, 45 were randomized to the teclistamab arm, while 14 were assigned to the control group receiving the standard lenalidomide plus dexamethasone regimen.
- June 2026 – EHA Congress: The data was unveiled in a late-breaking session in Stockholm, signaling a major shift in the treatment landscape. The report highlighted not only the efficacy of the drug but also its manageable safety profile, effectively challenging the current reliance on standard combination therapies.
Supporting Data: By the Numbers
The statistical significance of the ImmunoPRISM results is profound, revealing a stark contrast between the immunotherapy cohort and the control group.
Depth of Response
The depth of response achieved by teclistamab was unprecedented in this patient population:
- Complete Response (CR): 75.6% of patients in the teclistamab arm achieved a complete response, compared to 0% in the control group.
- Very Good Partial Response (VGPR): When expanding the metrics to include VGPR or better, 87% of the teclistamab group hit this milestone, compared to only 14% of those on lenalidomide/dexamethasone.
Minimal Residual Disease (MRD)
Perhaps the most critical indicator of long-term success is the status of Minimal Residual Disease. MRD-negativity signifies that cancer cells cannot be detected even by high-sensitivity testing.
- In the teclistamab group, 82% of evaluable patients achieved MRD-negativity.
- In the control group, 0% achieved MRD-negativity.
- Crucially, all MRD-negative responses remained durable at the time of the data cutoff, suggesting that the treatment is clearing the disease burden to an extent previously unseen in SMM.
Progression-Free Survival (PFS)
The survival metrics paint a clear picture of the clinical benefit. After a median follow-up of 23.4 months:
- Only 7% of patients in the teclistamab arm showed signs of disease progression.
- In contrast, 36% of patients in the control group progressed.
- Projections estimate a 92% survival rate without disease progression at two years for the teclistamab group, compared to just 51% for those on the standard combination therapy.
Official Responses and Clinical Perspectives
The clinical community has reacted with significant optimism. Dr. Omar Nadeem, Medical Director of the Center of Early Detection and Interception of Blood Cancers at Dana-Farber, emphasized the importance of the "rapid and deep" responses.
"These are striking results because this is the first randomized study to show that a BCMA-targeted bispecific therapy can outperform a lenalidomide-based approach in high-risk smoldering myeloma," Dr. Nadeem stated. "We saw rapid, deep responses… those responses have remained durable so far. These findings suggest that treating patients earlier—before they develop symptomatic multiple myeloma—may meaningfully change the trajectory of the disease."
Dr. Irene Ghobrial, Director of the Center for Early Detection and Interception of Blood Cancers, underscored the broader implications for cancer interception. "By harnessing the immune system before the onset of symptomatic disease, teclistamab may leverage preserved immune fitness and lower disease burden to achieve deeper, more durable disease control," Dr. Ghobrial noted.
Implications: The Future of "Interception"
The success of the ImmunoPRISM trial suggests that the medical community may be shifting toward a "myeloma interception" model. This approach relies on identifying patients at high risk of progression and treating them while the disease is still in its asymptomatic, smoldering state.
Safety and Tolerability
One of the primary concerns with T-cell redirection therapies is the risk of side effects, particularly cytokine release syndrome (CRS). In the ImmunoPRISM trial, 71% of patients experienced CRS, but all instances were categorized as "low grade." Furthermore, no neurological toxicities were observed, and rates of high-grade infections were lower than those typically seen in heavily pre-treated, relapsed/refractory patients. This suggests that the early intervention strategy is not only effective but also clinically tolerable for patients who are not yet experiencing the debilitating symptoms of active cancer.
A Paradigm Shift
If these findings are replicated in larger, confirmatory trials, the standard of care for high-risk SMM will likely undergo a significant transformation. Moving away from "watch and wait" toward active, immunotherapy-driven interception offers the potential to prevent the organ damage, bone lesions, and renal complications associated with full-blown multiple myeloma.
Moreover, by treating patients early, clinicians avoid the "immune exhaustion" that occurs after multiple rounds of therapy. Preserving the immune system’s integrity early in the disease course appears to be the "secret weapon" that allowed teclistamab to achieve such high rates of MRD-negativity.
Looking Ahead
As researchers continue to follow the ImmunoPRISM participants, the long-term data will be essential in confirming whether these responses translate into a definitive "cure" or long-term disease control. For the hematology community, the success of the trial serves as a clarion call to prioritize the early detection of blood cancers. With tools like teclistamab, the goal of preventing symptomatic cancer from ever developing is no longer a distant aspiration—it is an emerging clinical reality.
For patients living with the uncertainty of high-risk smoldering multiple myeloma, the ImmunoPRISM data offers a new horizon of hope, potentially sparing them from the progression to the more aggressive stages of the disease and significantly enhancing their quality of life.
About the Author
